Pfizer Total Current Assets 2012-2026 | PFE
Pfizer total current assets from 2012 to 2026. Total current assets can be defined as the sum of all assets that are classified as current because they will provide a benefit within one year.
- Pfizer total current assets for the quarter ending March 31, 2026 were $46.924B, a 8.56% increase year-over-year.
- Pfizer total current assets for 2024 were $50.358B, a 16.21% increase from 2023.
- Pfizer total current assets for 2023 were $43.333B, a 15.46% decline from 2022.
- Pfizer total current assets for 2022 were $51.259B, a 14.13% decline from 2021.
|
Pfizer Annual Total Current Assets (Millions of US $) |
|
|---|---|
| 2024 | $50,358 |
| 2023 | $43,333 |
| 2022 | $51,259 |
| 2021 | $59,693 |
| 2020 | $35,067 |
| 2019 | $32,803 |
| 2018 | $49,926 |
| 2017 | $41,141 |
| 2016 | $38,949 |
| 2015 | $43,804 |
| 2014 | $55,595 |
| 2013 | $56,244 |
| 2012 | $64,831 |
| 2011 | $60,817 |
|
Pfizer Quarterly Total Current Assets (Millions of US $) |
|
|---|---|
| 2025-09-30 | $46,924 |
| 2025-06-30 | $43,703 |
| 2025-03-31 | $45,861 |
| 2024-12-31 | $50,358 |
| 2024-09-30 | $43,223 |
| 2024-06-30 | $37,825 |
| 2024-03-31 | $42,415 |
| 2023-12-31 | $43,333 |
| 2023-09-30 | $74,012 |
| 2023-06-30 | $73,347 |
| 2023-03-31 | $50,078 |
| 2022-12-31 | $51,259 |
| 2022-09-30 | $70,403 |
| 2022-06-30 | $67,466 |
| 2022-03-31 | $54,420 |
| 2021-12-31 | $59,693 |
| 2021-09-30 | $57,900 |
| 2021-06-30 | $48,814 |
| 2021-03-31 | $39,533 |
| 2020-12-31 | $35,067 |
| 2020-09-30 | $47,739 |
| 2020-06-30 | $46,424 |
| 2020-03-31 | $34,738 |
| 2019-12-31 | $32,803 |
| 2019-09-30 | $33,459 |
| 2019-06-30 | $47,073 |
| 2019-03-31 | $45,290 |
| 2018-12-31 | $49,926 |
| 2018-09-30 | $41,583 |
| 2018-06-30 | $37,303 |
| 2018-03-31 | $34,835 |
| 2017-12-31 | $41,141 |
| 2017-09-30 | $40,291 |
| 2017-06-30 | $36,385 |
| 2017-03-31 | $35,878 |
| 2016-12-31 | $38,949 |
| 2016-09-30 | $38,501 |
| 2016-06-30 | $43,845 |
| 2016-03-31 | $41,298 |
| 2015-12-31 | $43,804 |
| 2015-09-30 | $45,001 |
| 2015-06-30 | $51,715 |
| 2015-03-31 | $49,443 |
| 2014-12-31 | $55,595 |
| 2014-09-30 | $56,987 |
| 2014-06-30 | $58,287 |
| 2014-03-31 | $57,793 |
| 2013-12-31 | $56,244 |
| 2013-09-30 | $59,500 |
| 2013-06-30 | $61,435 |
| 2013-03-31 | $64,763 |
| 2012-12-31 | $64,831 |
| 2012-09-30 | $57,127 |
| 2012-06-30 | $58,765 |
| 2012-03-31 | $54,863 |
| 2011-12-31 | $60,817 |
| 2011-09-30 | $62,732 |
| 2011-06-30 | $60,484 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $153.074B | $62.579B |
| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |